First-of-its-Kind cell therapy tested for MS
NCT ID NCT07303790
Summary
This is a very early study to see if a new type of cell therapy called GC012F is safe and tolerable for people with multiple sclerosis (MS). The therapy involves collecting a patient's own immune cells, modifying them in a lab to potentially target MS, and then infusing them back. The study will enroll 15 participants to closely monitor for side effects and gather initial data on how the cells behave in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology
RECRUITINGHubei, Hubei, 430030, China
Conditions
Explore the condition pages connected to this study.